reports
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. “We are thrilled to welcome Michael to Avalo’s Board of Directors during...
Avalo Reports 2024 Financial Results and Recent Business Updates
Avalo Reports 2024 Financial Results and Recent Business Updates Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial ...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in March. TD Cowen 45th Annual Health Care Conference, BostonCorporate PresentationMarch 3, 2025, at 3:10 pm ET Leerink Partners Global Healthcare Conference, Miami 1x1 and small group meetings March 12, 2025 Live webcasts and replays, when av...
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare ...
Avalo Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET. Live webcast and replay can be found under "News / Events" in the Investors...
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. “We are thrilled to welcome Jennifer to ...
Griffon Corp: 2 directors
Two Directors at Griffon Corp gave away/sold 9,170 shares at between 0.000USD and 80.380USD. The significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
Moody's Ratings upgrades Griffon's CFR to Ba3; stable outlook
Moody's Ratings (Moody's) upgraded Griffon Corporation's (Griffon) ratings including the Corporate Family Rating (CFR) to Ba3 from B1, Probability of Default Rating (PDR) to Ba3-PD from B1-PD, the rating on the company's senior secured first lien bank credit facility to Ba1 from Ba2, and the rating ...
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Ex...
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 millionCash runway expected into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that it has received $69.4 million in gross proceeds from the full ex...
Avalo Therapeutics to Present at Upcoming Investor Conferences
Avalo Therapeutics to Present at Upcoming Investor Conferences WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences: Stifel 2024 Healthcare Conference, New YorkMonday, November 18, 2024 at 3:35 PM ET Piper Sandler 36th Annual Healthcare Conference, New YorkWednesday, December 5, 2024 at 11:00 AM ET Live we...
Avalo Reports Third Quarter 2024 Financial Results and Recent Business...
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026Cash position of approximately $82 million as of September 30, 2024 with subsequent receipt of approximately $58 million of warrant exercise proceeds in 4Q 2024, provides expected runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatmen...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Bull Trap Still Brewing? The S&P 500 (SPX) continues to hold below 5783, which is the upper-end of an important target/resistance area (5670-5783) we have discussed since our 8/13/24 Compass, just after the SPX hit our 5100-5191 "expected pullback zone." 5670 was the prior all-time high set in July, while 5783 is 2% above 5670. The current "breakout" above 5670 is an extraordinarily weak one, which usually suggests a false breakout/bull trap is brewing; the SPX has spent nearly three weeks abov...
EME EMCOR GROUP
WLDN WILLDAN GROUP
TRN TRINITY INDUSTRIES INC.
TPC TUTOR PERINI CORPORATION
STRL STERLING CONSTRUCTION COMPANY INC.
PWR QUANTA SERVICES INC.
NWPX NORTHWEST PIPE CO.
MTZ MASTEC INC.
GVA GRANITE CONSTRUCTION INCORPORATED
DY DYCOM INDUSTRIES INC.
BWXT BWX TECHNOLOGIES INC.
FLR FLUOR CORPORATION
GLDD GREAT LAKES DREDGE & DOCK CORPORATION
KBR KBR INC.
PRIM PRIMORIS SERVICES CORPORATION
AGX ARGAN INC.
WAB WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORPORATION
ARCAY ARCADIS N.V.
ROAD CONSTRUCTION PARTNERS
BV BRIGHTVIEW HOLDINGS
BW BABCOCK & WILCOX ENTERPRISES
IESC IES HOLDINGS INC.
J JACOBS SOLUTIONS INC.
TISI TEAM INC.
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009...
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of AVTX-009 compared to placeboTopline data expected in 2026 WAYNE, Pa. and ROCKVILLE, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that the first patient has been dosed in the Company’s Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS). AVTX-009 is a humanized monoclonal antibody ...
Avalo Announces Participation in September Investor Conferences
Avalo Announces Participation in September Investor Conferences WAYNE, Pa. and ROCKVILLE, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ConferenceDates: September 9-11, 2024A pre-recorded presentation will be made available on Monday, September 9, 2024 at 7:00 AM ET. Stifel 2024 Virtual Immunology and Inflammation SummitFireside Chat Date: Tuesday, September 17, ...
Avalo Reports Second Quarter 2024 Financial Results and Provides Busin...
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates Expects to enroll first patient in Phase 2 LOTUS Trial of AVTX-009 in hidradenitis suppurativa in the second half of 2024Appointed Dr. Mittie Doyle as Chief Medical Officer and Paul Varki as Chief Legal OfficerCash on hand of approximately $93.4 million as of June 30, 2024 with expected cash runway into 2027 WAYNE, Pa. and ROCKVILLE, Md., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the second quarter of 2024. “The...
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief ...
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting time as we prepare to initiate our Phase 2 LOTUS Trial in patients with hidradenitis suppurativa. Mittie brings to Avalo a strong combination of drug development experience through all stages of development and exceptional ex...
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mA...
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β monoclonal antibody (mAb), for the treatment of hidradenitis suppurativa (HS) is n...
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal ...
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer. “We are delighted to have Paul join and grow our leadership team at an exciting time at Avalo following our acquisition and private placement earlier this year,” said Garry A. Neil, MD, CEO and Chairman of the Board at Avalo. “Paul’s deep industry experience will immediately enhance our strategic and legal competencies. Furt...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.